Radiotherapy
Combined quetiapine and radiation therapy approach to treat mesothelioma-initiating cells and increase survival in a mouse model of mesothelioma
bioRxiv 2025 April 14 [Link] Anjelica Cardenas, Evelyn Arambula, Linda Azizi, Tara Lam, Sabrina Sutlief, Kruttika Bhat, Mohammad Saki, Ling He, Frank Pajonk Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare thoracic cancer associated with poor prognosis and low survival rates. In solid cancers, repurposed dopamine receptor antagonists have been shown to have anti-cancer…
Read MoreThe Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma
Cancers 2025 April 20 [Link] Berta Mosleh, Katharina Sinn, Anna Cho, Anton Reiner, Ariane Steindl, Christian Lang, Sabine Zöchbauer-Müller, Karin Dieckmann, Joachim Widder, Helmut Prosch, Balazs Dome, Karin Schelch, Clemens Aigner, Thomas Klikovits, Michal Benej, Stefan Watzka, Martin Filipits, Servet Bölükbas, Pavla Sarova, Daniela Gompelmann, Michael Grusch, Mir Alireza Hoda Abstract Background/objectives: Malignant pleural mesothelioma…
Read MoreRadical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?
Frontiers in Immunology 2025 April 1 [Link] Alberto Revelant, Francesca Gessoni, Marcella Montico, Raja Dhibi, Giulia Brisotto, Mariateresa Casarotto, Martina Zanchetta, Veronica Paduano, Filippo Sperti, Chiara Evangelista, Fabiana Giordari, Valli De Re, Marco Trovò, Emilio Minatel, Maurizio Mascarin, Agostino Steffan, Elena Muraro Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure,…
Read MoreImpact of Neoadjuvant and Adjuvant Pleural Intensity-Modulated Radiotherapy in Multimodality Treatment for Malignant Pleural Mesothelioma
Thoracic Cancer 2025 March [Link] Berta Mosleh, Stefan Schwarz, Anna Cho, Katharina Sinn, Ariane Steindl, Sabine Zöchbauer-Müller, Wolfgang J Köstler, Karin Dieckmann, Martin Heilmann, Joachim Widder, Daniela Gompelmann, Clemens Aigner, Thomas Klikovits, Mir Alireza Hoda Abstract Background: Few malignancies provoke as many controversies about treatment as pleural mesothelioma. There is limited experience with novel radiotherapy…
Read MoreCurrent Status of Staging and Restaging Malignant Pleural Mesothelioma
Seminars in Nuclear Medicine 2025 March [Link] Egesta Lopci Malignant pleural mesothelioma (MPM) is the most frequent aggressive tumor affecting the pleura, accounting for over 38,000 deaths worldwide. It originates from the mesothelial cells and is mostly associated to asbestos exposure. Depending on the extent of the disease, the management of MPM varies from surgical…
Read MoreRadiotherapy of the pleural cavity in patients with primary and secondary malignancies of the pleura
Reports of Practical Oncology and Radiotherapy 2024 October 3 [Link] Dimcho Georgiev, Marija Jankova, Bozhidar Krastev, Svetlana Bilyukova Abstract Background: Although there have been various attempts to find appropriate treatment from best conservative care to multimodal treatments, curative outcomes remain poor. Materials and methods: 30 patients with primary and secondary malignant tumors of the pleura…
Read MoreThe impact of age on the efficacy of radiotherapy in pleural mesothelioma patients receiving trimodality therapy: a population-based study of the SEER database
Journal of Thoracic Disease 2024 October 31 [Link] Jun Yang, Liang Xia, Hui Jie, Tengyong Wang, Chenglin Guo, Chengwu Liu, Hu Liao, Jiandong Mei, Qiang Pu, Lunxu Liu Abstract Background: Pleural mesothelioma (PM) is a highly aggressive tumor with poor survival outcomes. The role of additional radiotherapy for PM patients who have received surgery and…
Read MoreFractionated low-dose radiotherapy primes the tumor microenvironment for immunotherapy in a murine mesothelioma model
Cancer Immunology, Immunotherapy 2025 January 3 [Link] Rebecca A D’Alonzo, Synat Keam, Suki Gill, Pejman Rowshanfarzad, Anna K Nowak, Martin A Ebert, Alistair M Cook Abstract Combination immune checkpoint inhibitors (nivolumab and ipilimumab) are currently a first-line treatment for mesothelioma; however, not all patients respond. The efficacy of treatment is influenced by the tumor microenvironment.…
Read MoreThe Role of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Thoracic Tumors
Cancers 2024 July 11 [Link] Federica Danuzzo, Maria Chiara Sibilia, Sara Vaquer, Andrea Cara, Enrico Mario Cassina, Lidia Libretti, Emanuele Pirondini, Federico Raveglia, Antonio Tuoro, Francesco Petrella Abstract Pleural mesothelioma (PM) is a rare but aggressive thoracic tumor with a poor prognosis. Multimodal treatment-including induction chemotherapy, aggressive surgical resection, radiotherapy and immunotherapy in selected cases-currently…
Read MoreExtensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT
World Journal of Nuclear Medicine 2023 December 4 [Link] Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2…
Read More